Showing results (111-120 of 980) with videos related to
Sort By:
Pageof 98
Cardiovascular Therapeutics|August 20, 2009
Drug treatment and cost of cardiovascular disease in AustraliaZanfina Ademi, Danny Liew, Derek Chew, et al.Cardiovascular Therapeutics|August 20, 2009
Prasugrel: a novel platelet ADP P2Y receptor antagonistWilliam Wilson, Ronen Gurvitch, Andrew E AjaniCardiovascular Therapeutics|November 28, 2008
Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjectsSujata Vaidyanathan, Michael Bartlett, Hans Armin Dieterich, et al.Cardiovascular Therapeutics|November 28, 2008
Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in ratsSoon-Pyo Hong, Dong-Hyun Choi, Jun-Shik ChoiCardiovascular Therapeutics|June 18, 2010
Chronotropic incompentence and functional capacity in chronic heart failure: no role of β-blockers and β-blocker doseDamiano Magrì, Pietro Palermo, Filippo M Cauti, et al.Cardiovascular Therapeutics|June 18, 2010
Cardiovascular implantable electronic devices in athletesRose Do, Kristen K PattonCardiovascular Therapeutics|June 18, 2010
The quest for new anticoagulants: from clinical development to clinical practiceStavros Apostolakis, Gregory Y H Lip, Deirdre A Lane, et al.Cardiovascular Therapeutics|June 18, 2010
Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritisLouise E Full, Claudia MonacoCardiovascular Therapeutics|June 18, 2010
Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?Roberto Scarpioni, Marco Ricardi, Luigi Melfa, et al.Cardiovascular Therapeutics|July 22, 2010
Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusionPaul J W H Kappelle, Arie van Tol, Bruce H R Wolffenbuttel, et al.Pageof 98